-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Early Stage
-
Expert Commentary on the Clinical and Surgical Implications of VPI in NSCLC
Dr. Ramón Rami-Porta offers a surgical perspective on the secondary analysis of the CALGB 140503 trial and discusses what, if any, influence the data will have on staging guidelines.
-
Adjuvant Alectinib for ALK+ NSCLC: An Interview with Dr. Benjamin Solomon
Speaking with Dr. Narjust Florez, Prof. Solomon discusses the design and results of the ALINA trial.
-
ADAURA: Data is Only Part of the Story
Patient Research Advocate (PRA) and 12-year survivor, Jill Feldman, discusses scientific and humanistic concerns regarding the ADAURA trials current data on disease-free progression in NSCLC. As a patient, osimertinib has given Ms. Feldman the hope that she has not had since her diagnosis. As a PRA, there are concerns about the lack of information about…
-
Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC
The randomized phase III ADAURA trial stirred up considerable excitement last year when results from an unplanned interim analysis revealed an 80% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib in comparison with placebo among patients with stage IB to IIIA NSCLC, far exceeding expectations for the global trial.1…
-
Redefining Good Quality Resections in NSCLC
Curative-intent resections for NSCLC often fail. Approximately 20% to 40% of patients with lung cancer who undergo curative-intent resection, experience a relapse, and die within 4 years. One key factor is the quality of the surgery, although there are no universal benchmarks of good quality resection, according to Raymond U. Osarogiagbon, MD, of the Thoracic…